💥 When High LDL Isn’t High Risk? New Study Says "Plaque Begets Plaque"—Not ApoB

Published April 2025 | Research spotlight

If you’ve ever worried about sky-high LDL-C or ApoB on a ketogenic diet, here’s some news that might shift your perspective.

A just-published paper in JACC: Advances titled “Plaque Begets Plaque, ApoB Does Not” (Soto-Mota et al., 2025) delivered one of the most nuanced looks yet at cardiovascular risk in a unique population: lean mass hyper-responders (LMHRs)—people who see dramatic increases in LDL-C and ApoB on a carb-restricted ketogenic diet, despite being metabolically healthy and lean.

Researchers followed 100 such individuals for one year, all of whom had been on a ketogenic diet for several years and showed marked increases in LDL-C (mean ~254 mg/dL) and ApoB (mean ~185 mg/dL). Using high-resolution coronary CT angiography and coronary artery calcium (CAC) scoring, they tracked coronary plaque progression in this population.

And here’s the clincher:

Individuals with a CAC score of 0 at baseline showed very low risk of plaque progression—despite their extremely elevated LDL-C and ApoB.

This finding was striking because it flips a core assumption on its head. In the conventional cardiovascular risk model, high LDL-C or ApoB is treated as a primary red flag. But this study suggests context is everything. For individuals with no detectable coronary calcium at baseline—meaning no measurable atherosclerotic plaque—their future risk of progression was minimal, regardless of lipid levels.

🔍 Translation? In this group, baseline plaque—not blood lipids—predicted future plaque.

The phrase “plaque begets plaque” sums up the authors’ findings. It wasn’t how high your LDL-C was, or how long it had been elevated—it was whether plaque was present to begin with.

Why It Matters

For clinicians and patients navigating the complexities of ketogenic diets and lipid labs, this study provides a crucial data point: high ApoB may not be universally atherogenic. The risk associated with elevated lipids appears to be highly dependent on individual metabolic context and pre-existing arterial health.

Caution and Next Steps

While this is promising, it’s not a free pass. The study ran for only one year and focused on a very specific, healthy, and adherent population. Longer-term data are still needed.

But if you—or your patient—is a lean, metabolically healthy individual on a ketogenic diet with high LDL but a clean CAC scan, this paper adds weight to a more personalized, imaging-informed approach to cardiovascular risk.

📘 Citation: Soto-Mota A, Norwitz NG, Manubolu VS, et al. Plaque Begets Plaque, ApoB Does Not: Longitudinal Data From the KETO-CTA Trial. JACC: Advances. 2025;101686. DOI:10.1016/j.jacadv.2025.101686